KR100520406B1 - 아미드 화합물을 포함하는 약제학적 조성물 - Google Patents

아미드 화합물을 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR100520406B1
KR100520406B1 KR10-2004-7009661A KR20047009661A KR100520406B1 KR 100520406 B1 KR100520406 B1 KR 100520406B1 KR 20047009661 A KR20047009661 A KR 20047009661A KR 100520406 B1 KR100520406 B1 KR 100520406B1
Authority
KR
South Korea
Prior art keywords
compound
reaction
dichloromethane
mixture
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR10-2004-7009661A
Other languages
English (en)
Korean (ko)
Other versions
KR20040063001A (ko
Inventor
야마다아키라
아오키사토시
Original Assignee
후지사와 야꾸힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후지사와 야꾸힝 고교 가부시키가이샤 filed Critical 후지사와 야꾸힝 고교 가부시키가이샤
Publication of KR20040063001A publication Critical patent/KR20040063001A/ko
Application granted granted Critical
Publication of KR100520406B1 publication Critical patent/KR100520406B1/ko
Assigned to 아스텔라스세이야쿠 가부시키가이샤 reassignment 아스텔라스세이야쿠 가부시키가이샤 권리의 전부이전등록 Assignors: 후지사와 야꾸힝 고교 가부시키가이샤
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR10-2004-7009661A 1999-01-14 2000-01-06 아미드 화합물을 포함하는 약제학적 조성물 Expired - Lifetime KR100520406B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP8180 1999-01-14
AUPP8180A AUPP818099A0 (en) 1999-01-14 1999-01-14 New n-containing heterocyclic compounds
PCT/JP2000/000017 WO2000042011A1 (en) 1999-01-14 2000-01-06 Amide compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR10-2001-7007314A Division KR100525809B1 (ko) 1999-01-14 2000-01-06 아미드 화합물

Publications (2)

Publication Number Publication Date
KR20040063001A KR20040063001A (ko) 2004-07-09
KR100520406B1 true KR100520406B1 (ko) 2005-10-11

Family

ID=3812385

Family Applications (2)

Application Number Title Priority Date Filing Date
KR10-2004-7009661A Expired - Lifetime KR100520406B1 (ko) 1999-01-14 2000-01-06 아미드 화합물을 포함하는 약제학적 조성물
KR10-2001-7007314A Expired - Lifetime KR100525809B1 (ko) 1999-01-14 2000-01-06 아미드 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR10-2001-7007314A Expired - Lifetime KR100525809B1 (ko) 1999-01-14 2000-01-06 아미드 화합물

Country Status (21)

Country Link
US (2) US6710043B1 (cg-RX-API-DMAC7.html)
EP (1) EP1140836B1 (cg-RX-API-DMAC7.html)
JP (2) JP3617454B2 (cg-RX-API-DMAC7.html)
KR (2) KR100520406B1 (cg-RX-API-DMAC7.html)
CN (1) CN1142910C (cg-RX-API-DMAC7.html)
AR (1) AR028812A1 (cg-RX-API-DMAC7.html)
AT (1) ATE502923T1 (cg-RX-API-DMAC7.html)
AU (1) AUPP818099A0 (cg-RX-API-DMAC7.html)
BR (1) BRPI0008753B8 (cg-RX-API-DMAC7.html)
CA (1) CA2360360C (cg-RX-API-DMAC7.html)
CZ (1) CZ20012562A3 (cg-RX-API-DMAC7.html)
DE (1) DE60045759D1 (cg-RX-API-DMAC7.html)
ES (1) ES2363492T3 (cg-RX-API-DMAC7.html)
HK (1) HK1044337B (cg-RX-API-DMAC7.html)
HU (1) HU230422B1 (cg-RX-API-DMAC7.html)
IL (2) IL143841A0 (cg-RX-API-DMAC7.html)
RU (1) RU2208608C2 (cg-RX-API-DMAC7.html)
TR (1) TR200102038T2 (cg-RX-API-DMAC7.html)
TW (1) TWI229075B (cg-RX-API-DMAC7.html)
WO (1) WO2000042011A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200104713B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
AU2002224046A1 (en) * 2000-12-07 2002-06-18 Fujisawa Pharmaceutical Co. Ltd. Nootropic effect enhancer
US7812035B2 (en) * 2001-12-11 2010-10-12 Sepracor Inc. 4-substituted piperidines, and methods of use thereof
ATE397861T1 (de) * 2002-12-06 2008-07-15 Dow Agrosciences Llc Synergistische zusammensetzungen
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2006045119A2 (en) 2004-10-20 2006-04-27 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US20080009477A1 (en) * 2004-11-04 2008-01-10 Neurogen Corporation Arylalkyl Ureas As Cb1 Antagonists
PL1940786T3 (pl) 2005-09-16 2010-12-31 Arrow Therapeutics Ltd Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
EP2081898A2 (en) * 2006-10-20 2009-07-29 Arete Therapeutics, INC. Adamantylurea compounds as soluble epoxide hydrolase inhibitors
CA2666482A1 (en) * 2006-10-20 2008-05-02 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
MX2009011250A (es) 2007-04-20 2009-11-05 Senju Pharma Co Promotor de la formacion de neuritas.
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
PL2207775T3 (pl) 2007-11-05 2012-08-31 Novartis Ag Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
AU2008333272B2 (en) 2007-12-03 2012-03-29 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
US8946197B2 (en) 2009-11-16 2015-02-03 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
EP4284804A1 (en) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939679B1 (cg-RX-API-DMAC7.html) * 1969-06-30 1974-10-28
US3647805A (en) * 1969-07-11 1972-03-07 Kyorin Seiyaku Kk Benzoylamino substituted 1-benzoyl-piperidines
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
GB1416872A (en) * 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
JPS5152176A (cg-RX-API-DMAC7.html) * 1974-10-12 1976-05-08 Yoshitomi Pharmaceutical
EP0002401B1 (fr) * 1977-11-24 1980-12-10 Synthelabo Dérivés de naphtalène, leur préparation et leur application en thérapeutique
DE3544244A1 (de) * 1985-12-14 1987-06-25 Minnesota Mining & Mfg Vorrichtung zum entnehmen von fuellgut aus beuteln
EP0255134B1 (en) 1986-07-31 1993-03-03 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof, process for preparing them, and cardiotonic composition containing same
CA1322199C (en) * 1987-07-15 1993-09-14 Masami Eigyo N-¬(2-oxopyrrolidin-1-yl) acetyl)| piperazine derivatives and drug for senile dementia
JPH0696575B2 (ja) * 1987-09-17 1994-11-30 三菱化成株式会社 4−アミノピリジン誘導体及びその酸付加塩
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
GB8917687D0 (en) * 1989-08-02 1989-09-20 Fujisawa Pharmaceutical Co Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
RU2024507C1 (ru) * 1991-11-18 1994-12-15 Евгений Яковлевич Левитин 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность
CA2077252C (en) * 1992-08-31 2001-04-10 Khashayar Karimian Methods of making ureas and guanidines, and intermediates therefor
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
CN1052224C (zh) * 1993-04-07 2000-05-10 大塚制药株式会社 哌啶衍生物、含有它的外周血管舒张剂及其应用
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
DE4319038A1 (de) * 1993-06-08 1994-12-15 Bayer Ag Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung
ATE204264T1 (de) * 1993-06-18 2001-09-15 Fujisawa Pharmaceutical Co Zwischenprodukt zur verwendung in der synthese und verfahren zur herstellung eines aminopiperazinderivates
US5500423A (en) * 1994-09-09 1996-03-19 Hoechst-Roussel Pharmaceuticals Inc. 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines
EP0820452B1 (en) * 1995-04-07 2003-06-04 Schering Corporation Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase
GB9519077D0 (en) * 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
US6077857A (en) * 1995-11-13 2000-06-20 Smithkline Beecham Corporation Hemoregulatory compounds
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
ZA9710872B (en) * 1996-12-12 1998-06-15 Fujisawa Pharmaceutical Co N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate.
KR20000057303A (ko) * 1996-12-24 2000-09-15 후지야마 아키라 아미노피페라진 유도체의 신규 용도
EP0968201A2 (en) 1997-02-17 2000-01-05 Fujisawa Pharmaceutical Co., Ltd. New aminopiperazine derivatives
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property

Also Published As

Publication number Publication date
JP3617454B2 (ja) 2005-02-02
KR20010093819A (ko) 2001-10-29
IL143841A (en) 2006-07-05
TR200102038T2 (tr) 2002-01-21
WO2000042011A1 (en) 2000-07-20
ATE502923T1 (de) 2011-04-15
JP2002534503A (ja) 2002-10-15
EP1140836A1 (en) 2001-10-10
HK1044337A1 (en) 2002-10-18
BRPI0008753B8 (pt) 2021-05-25
HUP0105108A3 (en) 2002-11-28
KR100525809B1 (ko) 2005-11-03
CZ20012562A3 (cs) 2001-11-14
KR20040063001A (ko) 2004-07-09
ES2363492T3 (es) 2011-08-05
AUPP818099A0 (en) 1999-02-11
ZA200104713B (en) 2002-09-09
TWI229075B (en) 2005-03-11
CA2360360C (en) 2009-09-08
HUP0105108A2 (hu) 2002-05-29
CN1142910C (zh) 2004-03-24
US20040014745A1 (en) 2004-01-22
AR028812A1 (es) 2003-05-28
IL143841A0 (en) 2002-04-21
BR0008753A (pt) 2001-11-06
US6710043B1 (en) 2004-03-23
BR0008753B1 (pt) 2013-11-12
CA2360360A1 (en) 2000-07-20
JP2004002414A (ja) 2004-01-08
HU230422B1 (hu) 2016-05-30
CN1336917A (zh) 2002-02-20
EP1140836B1 (en) 2011-03-23
HK1044337B (zh) 2004-11-26
RU2208608C2 (ru) 2003-07-20
DE60045759D1 (de) 2011-05-05

Similar Documents

Publication Publication Date Title
KR100525809B1 (ko) 아미드 화합물
US6291464B1 (en) Aminopiperazine derivatives
ES2240339T3 (es) Derivados de oxibenzamidas en calidad de inhibidores de factor xa.
AU675928B2 (en) Opioid diarylmethylpiperazines and piperidines
KR19990022448A (ko) 벤즈아미드 유도체 및 바소프레신 길항제로서의 그의 용도
US7612076B2 (en) Piperazinyl-pyridine derivatives
CA2258093A1 (en) Fibrinogen receptor antagonists
CA2436130A1 (en) Substituted indoles and their use as integrin antagonists
CN101679370A (zh) 香草素受体配体及其在制备药物中的用途
JP2002517480A (ja) インテグリンインヒビターとしてのフェニルアラニン誘導体
EP0923555A1 (en) Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders
JPH08504194A (ja) フィブリノーゲンレセプターアンタゴニスト
DE60130910T2 (de) Enamin-derivate als zell-adhäsionsmoleküle
KR19980702030A (ko) 타키키닌 수용체의 안타고니스트인 5-(4-치환된 피페리디닐-1)-3-아릴-펜탄산 유도체
KR100620406B1 (ko) 콜린작용 활성을 강화시키기 위한 아미드 화합물
WO2003028725A1 (en) 4-(1-piperidiny)-butylcarboxamide as d3 dopamine receptor subtype selective ligands
ES2344546T3 (es) Compuesto aliciclico sustituido con arilo y composicion farmaceutica que lo contiene.
KR950014568B1 (ko) 융합된 이미다조헤테로사이클릭 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
AU760434B2 (en) Amide compounds
KR20140085470A (ko) 바닐로이드 수용체 리간드로서의 아민 치환된 메탄설폰아미드 유도체
ES2396557T3 (es) Derivado de benciloxipropilamina
JP2008521874A (ja) グリコーゲンホスホリラーゼのインヒビターとして有用なピロロピリジン−2−カルボン酸アミド誘導体
JP2003535088A (ja) 2,7−ナフチリジン誘導体
JP2003535081A (ja) 3−置換イソキノリン−1−イル誘導体
MXPA01006630A (en) Amide compounds

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20040618

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20041122

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20041210

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20050722

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20051004

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20051005

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20080925

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20090925

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20101004

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20110920

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20120924

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20120924

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20130924

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20130924

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20141001

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20141001

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20150918

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20150918

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20160921

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20160921

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20170919

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20170919

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20180918

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20180918

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20190917

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20190917

Start annual number: 15

End annual number: 15

PC1801 Expiration of term

Termination date: 20200706

Termination category: Expiration of duration